Eli Lilly and Company

Gordon Nelson Arbuthnot

Wayne Douglas Luke

Kerry John Hartauer

Brian Weston Dalder

Robert Eugene Stratford, Jr

Glenn A Meyer

Karen Klapper Lomas

Robert E Stratford

This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Benzothiophenes, formulations containing same, and methods

This invention provides compounds of formula Iand pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Benzothiophenes formulations containing same and methods

The present invention relates to a pharmaceutical formulation, which comprises from 5 to 15% by weight of tamoxifen citrate and a first disintegrant which is croscarmellose sodium, the percentage by weight of croscarmellose sodium present in the formulation being chosen such that, in six 20 mg unit doses, an average of at least 65 percent by weight of the tamoxifen citrate in the formulation will dissolve within 10 minutes in 1000 mL of 0.02N hydrochloric acid at 37&deg; C. when stirred at 100 rpm.

Pharmaceutical formulation

Growing community of inventors

Indianapolis, IN, United States of America

Gordon Nelson Arbuthnot